Showing 721-730 of 7719 results for "".
Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentJuvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.Natural Ingredients and Their Applications in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/natural-ingredients-and-their-applications-in-dermatology/22022/Understanding the role of natural ingredients in therapeutic regimens may help physicians to harness these agents for maximum effect.From SDPA: JAKs, Black Boxes, and What It All Means
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-jaks-black-boxes-and-what-it-all-means/26286/Practitioners shouldn’t fear Janus kinase (JAK) inhibitors for their patients when appropriate, according to a wide-ranging expert chat at the 2024 SDPA Annual Summer Conference in San Diego. The conversation featured Matthew Zirwas, MD, a dermatologist with DOCS Dermatology, and Amy Spizuoco, DO, FDermwireTV: Counterfeit Botox Cases Widen; New HS Treatment Approved in Europe
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-counterfeit-botox-cases-widen-new-hs-treatment-approved-europe/24419/In this episode of DermwireTV, the use of counterfeit Botox continues to widen; a first-of-its-kind drug is approved in Europe for hidradenitis suppurativa; and the PA Perspective series provides tips for training and onboarding in a new practice.An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.Cognitive Bias And The Art of Doctoring
https://practicaldermatology.com/topics/practice-management/cognitive-bias-and-the-art-of-doctoring/23680/Rethinking the approach to diagnosis may reduce errors and improve patient interactions.How Artificial Intelligence and Chatbots are Enhancing Medical Experiences for Patients
https://practicaldermatology.com/topics/practice-management/how-artificial-intelligence-and-chatbots-are-enhancing-medical-experiences-for-patients/23570/Medical practices are leveraging technology to increase patient care and overall efficiencies to improve the all-around customer experience.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.Up the Authenticity Factor on Your Dermatology Social Media
https://practicaldermatology.com/topics/practice-management/up-the-authenticity-factor-on-your-dermatology-social-media/23423/Strike the right tone and find the balance needed to truly engage with your current and potential patients.